Deciding on the ideal first-line treatment for rare and advanced kidney cancer
Currently, doctors are unsure which is the best first-line treatment [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer
Interim results from an ongoing clinical trial of lenvatinib and [...]
Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer
A recent phase 1b clinical trial investigated the use of [...]
European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase 3 KEYNOTE-426 [...]
European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
ASCO 2019: First-line pembrolizumab for advanced kidney cancer
Two presentations on the results of the KEYNOTE-427 clinical trial [...]
Targeted therapies with immunotherapies in kidney cancer
The following video is an interview with Professor Thomas Powles [...]
Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC
The results from the following study were presented at the [...]
